Anixa biosciences stock.
Anixa Biosciences stock has received a consensus rating of buy. The average rating score is and is based on 12 buy ratings, 0 hold ratings, and 0 sell ratings. What was the 52-week low for Anixa ...
Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...Anixa Biosciences (ANIX) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, with a price target of $12.00 . The company’s shares closed last ...Dec 1, 2023 · Anixa Biosciences Stock Price, News & Analysis (NASDAQ:ANIX) $3.27 -0.07 (-2.10%) (As of 12/1/2023 ET) Compare Today's Range $3.25 $3.43 50-Day Range $2.85 $3.64 52-Week Range $2.75 $6.45 Volume 45,375 shs Average Volume 70,005 shs Market Capitalization $101.60 million P/E Ratio N/A Dividend Yield N/A Price Target $10.50 See the latest Anixa Biosciences Inc stock price (ANIX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.
Anixa Biosciences Stock Price, News & Analysis (NASDAQ:ANIX) $3.27 -0.07 (-2.10%) (As of 12/1/2023 ET) Compare Today's Range $3.25 $3.43 50-Day Range $2.85 $3.64 52-Week Range $2.75 $6.45 Volume 45,375 shs Average Volume 70,005 shs Market Capitalization $101.60 million P/E Ratio N/A Dividend Yield N/A Price Target $10.50The cell therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T therapy in that it targets the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of …
Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock. News provided by. Anixa Biosciences, Inc. 22 Mar, 2021, 17:18 ET. SAN JOSE, Calif., March 22, 2021 /PRNewswire ...
Discover historical prices for ANIX stock on Yahoo Finance. View daily, weekly or monthly format back to when Anixa Biosciences, Inc. stock was issued.Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial. SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 – 3, 2023.Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Analyst's Opinion · Consensus Rating. Anixa Biosciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' consensus ...
SAN JOSE, Calif., Sept. 14, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases ...
Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology. Anixa’s programs are using the body’s immune system to …
Get Anixa Biosciences Inc (ANIX.PH) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsSAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...According to 1 Wall Street analyst that have issued a 1 year ANIX price target, the average ANIX price target is $12.00, with the highest ANIX stock price ...Research Anixa Biosciences' (Nasdaq:ANIX) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and ...In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $12.00. Yi Chen has given Anixa Biosciences ...ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
About ANIX Stock Exchange Ticker Symbol Financial Performance Financial Statements Analyst Forecast According to 2 analysts, the average rating for ANIX stock …Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board CI Oct. 13: Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial CIAnixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual ...Anixa Biosciences, Inc. is estimated to report earnings on 03/10/2023. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks ...Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock. News provided by. Anixa Biosciences, Inc. 22 Mar, 2021, 17:18 ET. SAN JOSE, Calif., March 22, 2021 /PRNewswire ...
SAN JOSE, Calif., Oct. 3, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...
SAN JOSE, Calif., July 20, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that due to public health and safety concerns related to the ongoing COVID-19 global pandemic and to support the health and well-being of its …Anixa Biosciences Inc stock performance at a glance. Check Anixa Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Anixa Biosciences, Inc. company earnings calendar and analyst expectations - Upcoming and past events | BOERSE MUENCHEN: CY71 | BOERSE MUENCHENThe cell therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T therapy in that it targets the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of …Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Anixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively Buying benzinga.com - July 24 at 8:26 AM: Vir Biotechnology (VIR) Down on Influenza Study Failure finance.yahoo.com - July 21 at 2:49 PM: Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Buys 5,500 Shares of Stock marketbeat.com - July 21 at …Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Track Anixa Biosciences Inc (ANIX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a …
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology ... Anixa Biosciences, Inc. today announced that its partner, Cleveland Clinic, ...
Anixa Biosciences, Inc. Common Stock (ANIX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
SAN JOSE - Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of the Company's breast cancer vaccine with Keytruda (pembrolizumab).Anixa Biosciences And 2 Other Penny Stocks Insiders Are Aggressively Buying benzinga.com - July 24 at 8:26 AM: Vir Biotechnology (VIR) Down on Influenza Study Failure finance.yahoo.com - July 21 at 2:49 PM: Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Buys 5,500 Shares of Stock marketbeat.com - July 21 at …Discover Anixa Biosciences' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. ... Lead Independent Director exercised options to buy US$119k worth of stock. Aug 02. Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on …Analyst's Opinion · Consensus Rating. Anixa Biosciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' consensus ...Earnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.32) to ($0.37) per share. Anixa Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 3rd, 2024 based off prior year's report dates. Read More.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. Anixa Biosciences, Inc. company earnings calendar and analyst expectations - Upcoming and past events | BOERSE MUENCHEN: CY71 | BOERSE MUENCHENA high-level overview of Anixa Biosciences, Inc. (ANIX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its CEO, Dr. Amit Kumar, will ...About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 ...SAN JOSE, Calif. and STUTTGART, Germany, Dec. 7, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and ...Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Instagram:https://instagram. how much is 1 gold bullion worthinvest in penny stocks appbanco bilbao vizcaya mexicoweightwatchers international SAN JOSE - Anixa Biosciences, Inc. ('Anixa' or the 'Company') (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 - 3, 2023. The presentation, entitled 'Infusion of Autologous T Cells … first wave biopharma stockhealixa Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt ...Investors. Overview. News Releases. Events & Presentations. Stock Info. SEC Filings. Financial Reports. suspende Discover historical prices for ANIX stock on Yahoo Finance. View daily, weekly or monthly format back to when Anixa Biosciences, Inc. stock was issued.Jun 22, 2023 · ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a …